<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39340031</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-393X</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>01</Day></PubDate></JournalIssue><Title>Vaccines</Title><ISOAbbreviation>Vaccines (Basel)</ISOAbbreviation></Journal><ArticleTitle>Safety and Immunogenicity of the Intranasal Vaccine Candidate Mambisa and the Intramuscular Vaccine Abdala Used as Booster Doses for COVID-19 Convalescents: A Randomized Phase 1-2 Clinical Trial.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1001</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/vaccines12091001</ELocationID><Abstract><AbstractText>A phase 1-2, prospective, multicenter, randomized, open-label clinical trial (Code RPCEC00000382), with parallel groups, involving 1161 participants, was designed to assess the safety and immunogenicity of two Cuban COVID-19 vaccines (Mambisa and Abdala) in boosting COVID-19 immunity of convalescent adults after receiving one dose of either vaccine. The main safety outcome was severe vaccination adverse events occurring in &lt;5% of vaccinees. Main immunogenicity success endpoints were a ≥4-fold anti-RBD IgG seroconversion or a ≥20% increase in ACE2-RBD inhibitory antibodies in &gt;55% of vaccinees in Phase 1 and &gt;70% in Phase 2. Neutralizing antibody titers against SARS-CoV-2 variants were evaluated. Both vaccines were safe-no deaths or severe adverse events occurred. Mild intensity adverse events were the most frequent (&gt;73%); headaches predominated for both vaccines. Phase 1 responders were 83.3% (<i>p</i> = 0.0018) for Abdala. Mambisa showed similar results. Phase 2 responders were 88.6% for Abdala (<i>p</i> &lt; 0.0001) and 74.2% for Mambisa (<i>p</i> = 0.0412). In both phases, anti-RBD IgG titers, inhibition percentages and neutralizing antibody titers increased significantly after the booster dose. Both vaccines were safe and their immunogenicity surpassed the study endpoints.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lemos-Pérez</LastName><ForeName>Gilda</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0003-0596-6501</Identifier><AffiliationInfo><Affiliation>Center for Genetic Engineering and Biotechnology (CIGB), P.O. Box 6162, La Habana 10600, Cuba.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barrese-Pérez</LastName><ForeName>Yinet</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>National Coordinating Center for Clinical Trials (CENCEC), La Habana 11300, Cuba.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chacón-Quintero</LastName><ForeName>Yahima</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Center for Genetic Engineering and Biotechnology (CIGB), P.O. Box 6162, La Habana 10600, Cuba.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uranga-Piña</LastName><ForeName>Rolando</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>National Coordinating Center for Clinical Trials (CENCEC), La Habana 11300, Cuba.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Avila-Albuerne</LastName><ForeName>Yisel</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>National Coordinating Center for Clinical Trials (CENCEC), La Habana 11300, Cuba.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Figueroa-García</LastName><ForeName>Iglermis</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Hermanos Ameijeiras Clinical-Surgical Hospital, La Habana 10400, Cuba.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Calderín-Marín</LastName><ForeName>Osaida</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Manuel Ascunce Domenech Provincial Clinical-Surgical Teaching Hospital, Camagüey 70100, Cuba.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gómez-Vázquez</LastName><ForeName>Martha M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Pedro Raúl Sánchez Teaching Polyclinic, Pinar del Río 20100, Cuba.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Piñera-Martínez</LastName><ForeName>Marjoris</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Saturnino Lora Provincial Clinical-Surgical Hospital, Santiago de Cuba 90100, Cuba.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chávez-Valdés</LastName><ForeName>Sheila</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center for Genetic Engineering and Biotechnology (CIGB), P.O. Box 6162, La Habana 10600, Cuba.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martínez-Rosales</LastName><ForeName>Ricardo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Center for Genetic Engineering and Biotechnology (CIGB), P.O. Box 6162, La Habana 10600, Cuba.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ávila-Díaz</LastName><ForeName>Lismary</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Center for Genetic Engineering and Biotechnology (CIGB), P.O. Box 6162, La Habana 10600, Cuba.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vázquez-Arteaga</LastName><ForeName>Amalia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Center for Genetic Engineering and Biotechnology (CIGB), P.O. Box 6162, La Habana 10600, Cuba.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>González-Formental</LastName><ForeName>Hany</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Center for Genetic Engineering and Biotechnology (CIGB), P.O. Box 6162, La Habana 10600, Cuba.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Freyre-Corrales</LastName><ForeName>Giselle</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Center for Genetic Engineering and Biotechnology (CIGB), P.O. Box 6162, La Habana 10600, Cuba.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coizeau-Rodríguez</LastName><ForeName>Edelgis</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Center for Genetic Engineering and Biotechnology (CIGB), P.O. Box 6162, La Habana 10600, Cuba.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Limonta-Fernández</LastName><ForeName>Miladys</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Center for Genetic Engineering and Biotechnology (CIGB), P.O. Box 6162, La Habana 10600, Cuba.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ayala-Avila</LastName><ForeName>Marta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Center for Genetic Engineering and Biotechnology (CIGB), P.O. Box 6162, La Habana 10600, Cuba.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martínez-Díaz</LastName><ForeName>Eduardo</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Ministry of Science, Technology and Environment (CITMA), La Habana 10400, Cuba.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pimentel-Vazquez</LastName><ForeName>Eulogio</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Biotechnology and Pharmaceutical Industries Group (BioCubaFarma), La Habana 10800, Cuba.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guillen</LastName><ForeName>Gerardo</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0003-3098-0970</Identifier><AffiliationInfo><Affiliation>Center for Genetic Engineering and Biotechnology (CIGB), P.O. Box 6162, La Habana 10600, Cuba.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Latin American School of Medicine (ELAM), La Habana 19108, Cuba.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Vaccines (Basel)</MedlineTA><NlmUniqueID>101629355</NlmUniqueID><ISSNLinking>2076-393X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19 vaccines</Keyword><Keyword MajorTopicYN="N">Cuba</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">booster</Keyword><Keyword MajorTopicYN="N">convalescents</Keyword><Keyword MajorTopicYN="N">intramuscular</Keyword><Keyword MajorTopicYN="N">intranasal</Keyword><Keyword MajorTopicYN="N">vaccination</Keyword></KeywordList><CoiStatement>The authors G.L.P., Y.C.Q., S.C.V., R.M.R., L.A.D., A.V.A., H.G.F., G.F.C., E.C.R., M.L.F., M.A.A. and G.G. are employees of the Center for Genetic Engineering and Biotechnology in Havana, where the active ingredients of the Abdala and Mambisa vaccines were produced and where the vaccine formulations were developed. The rest of the authors have no conflicts of interest. The funders had no role in the design of the study, in the collection, analyses, or interpretation of the data, in the writing of the manuscript, or in the decision to publish the results. None of the authors has received honoraria, consulting fees, or payments for seminar presentations, speeches, or appearances.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>7</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39340031</ArticleId><ArticleId IdType="pmc">PMC11435458</ArticleId><ArticleId IdType="doi">10.3390/vaccines12091001</ArticleId><ArticleId IdType="pii">vaccines12091001</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization  . WHO Director-General’s Opening Remarks at the Media Briefing on COVID-19. World Health Organization; Geneva, Switzerland: 2020.  [(accessed on 2 January 2024)].  Available online:  https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020.</Citation></Reference><Reference><Citation>Rossi M.A., Cena T., Binala J., Alessi D., Scotti D., Faggiano F. Evaluation of the risk of SARS-CoV-2 infection and hospitalization in vaccinated and previously infected subjects based on real world data. Sci. Rep. 2023;13:2018. doi: 10.1038/s41598-023-28129-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-023-28129-7</ArticleId><ArticleId IdType="pmc">PMC9897610</ArticleId><ArticleId IdType="pubmed">36737460</ArticleId></ArticleIdList></Reference><Reference><Citation>Pilz S., Theiler-Schwetz V., Trummer C., Krause R., Ioannidis J.P.A. SARS-CoV-2 reinfections: Overview of efficacy and duration of natural and hybrid immunity. Environ. Res. 2022;209:112911. doi: 10.1016/j.envres.2022.112911.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.envres.2022.112911</ArticleId><ArticleId IdType="pmc">PMC8824301</ArticleId><ArticleId IdType="pubmed">35149106</ArticleId></ArticleIdList></Reference><Reference><Citation>Altarawneh H.N., Hasan M.R., Ayoub H.H., Qassim S., Coyle P., Yassine H.M., Al-Kanaani Z., Abdul-Rahim H.F., Al-Kuwari M.G., Butt A.A., et al. Protection against the omicron variant from previous SARS-CoV-2 infection. N. Engl. J. Med. 2022;386:1288–1290. doi: 10.1056/NEJMc2200133.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2200133</ArticleId><ArticleId IdType="pmc">PMC8849180</ArticleId><ArticleId IdType="pubmed">35139269</ArticleId></ArticleIdList></Reference><Reference><Citation>Bobrovitz N., Ware H., Ma X., Li Z., Hosseini R., Cao C., Selemon A., Whelan M., Premji Z., Issa H., et al. Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: A systematic review and meta-regression. Lancet Infect. Dis. 2023;23:556–557. doi: 10.1016/S1473-3099(22)00801-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00801-5</ArticleId><ArticleId IdType="pmc">PMC10014083</ArticleId><ArticleId IdType="pubmed">36681084</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorry C. Vaccines and Public Trust: Containing COVID-19 in Cuba. Verena Muzio-González PhD Director of Clinical Research; Genetic Engineering and Biotechnology Center. MEDICC Rev. 2022;24:9–13. doi: 10.37757/MR2022.V24.N1.11.</Citation><ArticleIdList><ArticleId IdType="doi">10.37757/MR2022.V24.N1.11</ArticleId><ArticleId IdType="pubmed">35157633</ArticleId></ArticleIdList></Reference><Reference><Citation>Limonta-Fernández M., Chinea-Santiago G., Martín-Dunn A.M., Gonzalez-Roche D., Bequet-Romero M., Marquez-Perera G., González-Moya I., Canaan-Haden-Ayala C., Cabrales-Rico A., Espinosa-Rodríguez L.A., et al. An engineered SARS-CoV-2 receptor-binding domain produced in Pichia pastoris as a candidate vaccine antigen. New Biotechnol. 2022;72:11–21. doi: 10.1016/j.nbt.2022.08.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbt.2022.08.002</ArticleId><ArticleId IdType="pmc">PMC9359770</ArticleId><ArticleId IdType="pubmed">35953030</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernández-Bernal F., Ricardo-Cobas M.C., Martín-Bauta Y., Navarro-Rodríguez Z., Piñera-Martínez M., Quintana-Guerra J., Urrutia-Pérez K., Chávez-Chong C.O., Azor-Hernández J.L., Rodríguez-Reinoso J.L., et al. Safety; tolerability; and immunogenicity of a SARS-CoV-2 recombinant spike RBD protein vaccine: A randomised; double-blind; placebo-controlled; phase 1-2 clinical trial (ABDALA Study) eClinicalMedicine. 2022;46:101383. doi: 10.1016/j.eclinm.2022.101383.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2022.101383</ArticleId><ArticleId IdType="pmc">PMC8994669</ArticleId><ArticleId IdType="pubmed">35434578</ArticleId></ArticleIdList></Reference><Reference><Citation>Registro Público Cubano de Ensayos Clínicos (CU)  Ensayo Clínico Fase I/II Adaptativo; Aleatorizado; de Grupos Paralelos; para Evaluar la Seguridad e Inmunogenicidad en Adultos de dos Candidatos Vacunales; Basados en Subunidades de RBD Recombinante para la Prevención de COVID-19 en Esquemas que Emplean la vía de Administración nasal. Estudio MAMBISA.  [(accessed on 2 January 2024)].  Available online:  https://rpcec.sld.cu/ensayos/RPCEC00000345-Sp. (In Spanish)</Citation></Reference><Reference><Citation>Registro Público Cubano de Ensayos Clínicos (CU)  Evaluación del efecto y la seguridad de una dosis de refuerzo de Mambisa o Abdala contra la COVID-19 (Estudio BACONAO)  [(accessed on 2 January 2024)].  Available online:  https://rpcec.sld.cu/ensayos/RPCEC00000398-Sp. (In Spanish)</Citation></Reference><Reference><Citation>Centro para el Control Estatal de Medicamentos. Equipos y Dispositivos Médicos (CECMED) (CU)  ABDALA 50 μg (Vacuna anti COVID-19 de subunidad proteica). Resumen de las Características del Producto. 2021. Havana: CECMED. 2021.  [(accessed on 19 July 2023)].  Available online:  https://www.cecmed.cu/registro/rcp/biologicos/abdala-50-mg-vacuna-anti-covid-19-subunidad-proteica. (In Spanish)</Citation></Reference><Reference><Citation>Hernández-Bernal F., Ricardo-Cobas M.C., Martín-Bauta Y., Rodríguez-Martínez E., Urrutia-Pérez K., Quintana-Guerra J., Navarro-Rodríguez Z., Piñera-Martínez M., Rodríguez-Reinoso J.L., Chávez-Chong C.O., et al. A phase 3; randomised; double-blind; placebo-controlled clinical trial evaluation of the efficacy and safety of a SARS-CoV-2 recombinant spike RBD protein vaccine in adults (ABDALA-3 study) Lancet Reg. Health Am. 2023;21:100497. doi: 10.1016/j.lana.2023.100497.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lana.2023.100497</ArticleId><ArticleId IdType="pmc">PMC10160525</ArticleId><ArticleId IdType="pubmed">37192953</ArticleId></ArticleIdList></Reference><Reference><Citation>Más-Bermejo P.I., Dickinson-Meneses F.O., Almenares-Rodríguez K., Sánchez-Valdés L., Guinovart-Díaz R., Vidal-Ledo M., Galbán-García E., Olivera-Nodarse Y., Morgado-Vega I., Dueñas-Carrera S., et al. Cuban Abdala Vaccine: Effectiveness in Preventing Severe Disease and Death from COVID-19 in Havana Cuba; a Cohort Study. Lancet Reg. Health Am. 2022;16:100366. doi: 10.1016/j.lana.2022.100366.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lana.2022.100366</ArticleId><ArticleId IdType="pmc">PMC9507841</ArticleId><ArticleId IdType="pubmed">36185968</ArticleId></ArticleIdList></Reference><Reference><Citation>Cinza-Estévez Z., Resik-Aguirre S., Figueroa-Baile N.L., Oquendo-Martínez R., Campa-Legrá I., Tejeda-Fuentes A., Rivero-Caballero M., González-García G., Chávez-Chong C.O., Alonso-Valdés M., et al. Immunogenicity and safety assessment of a SARS-CoV-2 recombinant spike RBD protein vaccine (Abdala) in paediatric ages 3–18 years old: A double-blinded; multicentre; randomised; phase 1/2 clinical trial (ISMAELILLO study) eClinicalMedicine. 2023;63:102160. doi: 10.1016/j.eclinm.2023.102160.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2023.102160</ArticleId><ArticleId IdType="pmc">PMC10462868</ArticleId><ArticleId IdType="pubmed">37649806</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguilar-Estrada J.A., Anaya-Herazo C.A., Trujillo-Ricaño M., Navarro-Marín E., Sosa-Leyva M. COVID-19 y uso de vacunación de emergencia en el embarazo.  [(accessed on 2 January 2024)];Rev. Cubana. Obstetr. Ginecol. 2022 48:e1131. Available online:  https://revginecobstetricia.sld.cu/index.php/gin/article/view/362. (In Spanish)</Citation></Reference><Reference><Citation>Centro para el Control Estatal de Medicamentos. Equipos y Dispositivos Médicos (CECMED) (CU) Mambisa (CIGB 669 y CIGB 66) Aprobación. Ensayo Clínico Fase I/II Adaptativo. Aleatorizado. de Grupos Paralelos. para Evaluar la Seguridad e Inmunogenicidad en Adultos de dos Candidatos Vacunales. Basados en Subunidades de RBD Recombinante para la Prevención de COVID-19 en Esquemas que Emplean la vía de Administración Nasal  (COVID-19)  [(accessed on 2 January 2024)].  Available online:  https://www.cecmed.cu/covid-19/aprobaciones/mambisa-cigb-669-cigb-66.</Citation></Reference><Reference><Citation>Lemos-Perez G., Chavez-Valdes S., Gonzalez-Formental H., Freyre-Corrales G., Vazquez-Arteaga A., Alvarez-Acevedo B., Avila-Díaz L., Martínez-Rosales R.U., Chacon-Quintero Y., Coizeau-Rodriguez E., et al. Elevated Antibody Titers in Abdala Vaccinees Evaluated by Elecsys® Anti-SARS-Cov-2 S Highly Correlate with UMELISA SARS-Cov-2 ANTI RBD.; ACE-2 Binding Inhibition and Viral Neutralization Assays. J. Biotechnol. Biomed. 2022;5:151–157. doi: 10.26502/jbb.2642-91280055.</Citation><ArticleIdList><ArticleId IdType="doi">10.26502/jbb.2642-91280055</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson V.A., Byington R.E., Nara P.L. Quantitative Assays for Virus Infectivity. In: Aldovini A., Walker B.D., editors. Techniques in HIV Research. Volume 5. Palgrave Macmillan; London, UK: 1990. pp. 87–119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-349-11888-5_4</ArticleId></ArticleIdList></Reference><Reference><Citation>Anand P., Stahel V.P. The safety of Covid-19 mRNA vaccines: A review. Patient Saf. Sur. 2021;15:20. doi: 10.1186/s13037-021-00291-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13037-021-00291-9</ArticleId><ArticleId IdType="pmc">PMC8087878</ArticleId><ArticleId IdType="pubmed">33933145</ArticleId></ArticleIdList></Reference><Reference><Citation>Mannar D., Saville J.W., Zhu X., Srivastava S.S., Berezuk A.M., Tuttle K.S., Marquez A.C., Sekirov I., Subramaniam S. SARS-CoV-2 Omicron variant: Antibody evasion and cryo-EM structure of spike protein-ACE2 complex. Science. 2022;375:760–764. doi: 10.1126/science.abn7760.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abn7760</ArticleId><ArticleId IdType="pmc">PMC9799367</ArticleId><ArticleId IdType="pubmed">35050643</ArticleId></ArticleIdList></Reference><Reference><Citation>Cele S., Jackson L., Khoury D.S., Khan K., Moyo-Gwete T., Tegally H., San J.E., Cromer D., Scheepers C., Amoako D.G., et al. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature. 2022;602:654–656. doi: 10.1038/s41586-021-04387-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-04387-1</ArticleId><ArticleId IdType="pmc">PMC8866126</ArticleId><ArticleId IdType="pubmed">35016196</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertrand D., Hamzaoui M., Lemée V., Lamulle J., Laurent C., Etienne I., Lemoine M., Lebourg L., Hanoy M., Le Roy F., et al. Antibody and T-cell response to a third dose of SARS-CoV-2 mRNA BNT162b2 vaccine in kidney transplant recipients. Kidney Int. 2021;100:1337–1340. doi: 10.1016/j.kint.2021.09.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2021.09.014</ArticleId><ArticleId IdType="pmc">PMC8489274</ArticleId><ArticleId IdType="pubmed">34619232</ArticleId></ArticleIdList></Reference><Reference><Citation>Zambrana J.V., Saenz C., Maier H.E., Brenes M., Nuñez A., Matamoros A., Hernández M., Dumas K., Toledo C., Peralta L., et al. Comparative Analysis of SARS-CoV-2 Antibody Responses across Global and Lesser-Studied Vaccines. Vaccines. 2024;12:326. doi: 10.3390/vaccines12030326.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines12030326</ArticleId><ArticleId IdType="pmc">PMC10975599</ArticleId><ArticleId IdType="pubmed">38543960</ArticleId></ArticleIdList></Reference><Reference><Citation>Munson S., Parker J., King T.H., Lu Y., Kelley V., Guo Z., Borges V., Franzusoff A. Coupling innate and adaptive immunity with yeast-based cancer immunotherapy. In: Orentas R., Hodge J.W., Johnson B.D., editors. Cancer Vaccines and Tumor Immunity. John Wiley &amp; Sons; Hoboken, NJ, USA: 2008. pp. 131–149.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/9780470170113.ch9</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler S.E., Crowley A.R., Natarajan H., Xu S., Weiner J.A., Bobak C.A., Mattox D.E., Lee J., Wieland-Alter W., Connor R.I., et al. Distinct Features and Functions of Systemic and Mucosal Humoral Immunity Among SARS-CoV-2 Convalescent Individuals. Front. Immunol. 2021;11:618685. doi: 10.3389/fimmu.2020.618685.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.618685</ArticleId><ArticleId IdType="pmc">PMC7876222</ArticleId><ArticleId IdType="pubmed">33584712</ArticleId></ArticleIdList></Reference><Reference><Citation>Alu A., Chen L., Lei H., Wei Y., Tian X., Wei X. Intranasal COVID-19 vaccines: From bench to bed. eBioMedicine. 2022;76:103841. doi: 10.1016/j.ebiom.2022.103841.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2022.103841</ArticleId><ArticleId IdType="pmc">PMC8785603</ArticleId><ArticleId IdType="pubmed">35085851</ArticleId></ArticleIdList></Reference><Reference><Citation>Miquel-Clopés A., Bentley E.G., Stewart J.P., Carding S.R. Mucosal vaccines and technology. Clin. Exp. Immunol. 2019;196:205–214. doi: 10.1111/cei.13285.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cei.13285</ArticleId><ArticleId IdType="pmc">PMC6468177</ArticleId><ArticleId IdType="pubmed">30963541</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris A.S. Review: Clinical opportunities provided by the nasal administration of peptides. J. Drug Target. 1993;1:101–116. doi: 10.3109/10611869308996066.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/10611869308996066</ArticleId><ArticleId IdType="pubmed">8069548</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguilar J.C., Aguiar J.A., Akbar S.M.F. Action Mechanisms and Scientific Rationale of Using Nasal Vaccine (HeberNasvac) for the Treatment of Chronic Hepatitis, B. Vaccines. 2022;10:2087. doi: 10.3390/vaccines10122087.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10122087</ArticleId><ArticleId IdType="pmc">PMC9787858</ArticleId><ArticleId IdType="pubmed">36560498</ArticleId></ArticleIdList></Reference><Reference><Citation>Madhavan M., Ritchie A.J., Aboagye J., Jenkin D., Provstgaad-Morys S., Tarbet I., Woods D., Davies S., Baker M., Platt A., et al. Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial. eBioMedicine. 2022;85:104298. doi: 10.1016/j.ebiom.2022.104298.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2022.104298</ArticleId><ArticleId IdType="pmc">PMC9550199</ArticleId><ArticleId IdType="pubmed">36229342</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh C., Verma S., Reddy P., Diamond M.S., Curiel D.T., Patel C., Jain M.K., Redkar S.V., Bhate A.S., Gundappa V., et al. Phase III Pivotal comparative clinical trial of intranasal (iNCOVACC) and intramuscular COVID 19 vaccine (Covaxin®) Npj Vaccines. 2023;8:125. doi: 10.1038/s41541-023-00717-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-023-00717-8</ArticleId><ArticleId IdType="pmc">PMC10439197</ArticleId><ArticleId IdType="pubmed">37596281</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans J.P., Zeng C., Carlin C., Lozanski G., Saif L.J., Oltz E.M., Gumina R.J., Liu S.-L. Neutralizing antibody responses elicited by SARS-CoV-2 mRNA vaccination wane over time and are boosted by breakthrough infection. Sci. Transl. Med. 2022;14:eabn8057. doi: 10.1126/scitranslmed.abn8057.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abn8057</ArticleId><ArticleId IdType="pmc">PMC8939766</ArticleId><ArticleId IdType="pubmed">35166573</ArticleId></ArticleIdList></Reference><Reference><Citation>Guzmán M.G., Pérez L., Tejero Y., Mederos D., Aguado M.E., Pintos Y., Valdes V., Álvarez M., de Regla Ponce de León L., Baldoquín W., et al. Emergence and evolution of SARS-CoV-2 genetic variants during the Cuban epidemic. J. Clin. Virol. Plus. 2022;2:100104. doi: 10.1016/j.jcvp.2022.100104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcvp.2022.100104</ArticleId><ArticleId IdType="pmc">PMC9394106</ArticleId><ArticleId IdType="pubmed">36034515</ArticleId></ArticleIdList></Reference><Reference><Citation>Cromer D., Steain M., Reynaldi A., E Schlub T., Wheatley A.K., A Juno J., Kent S.J., A Triccas J., Khoury D.S., Davenport M.P. Neutralising antibody titres as predictors of protection against SARSCoV-2 variants and the impact of boosting: A meta-analysis. Lancet Microbe. 2022;3:E52–E61. doi: 10.1016/S2666-5247(21)00267-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-5247(21)00267-6</ArticleId><ArticleId IdType="pmc">PMC8592563</ArticleId><ArticleId IdType="pubmed">34806056</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattiuzzi C., Lippi G. Efficacy of COVID 19 vaccine booster doses in older people. Eur. Geriatr. Med. 2022;13:275–278. doi: 10.1007/s41999-022-00615-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s41999-022-00615-7</ArticleId><ArticleId IdType="pmc">PMC8784276</ArticleId><ArticleId IdType="pubmed">35067909</ArticleId></ArticleIdList></Reference><Reference><Citation>Henry C., Zheng N.-Y., Huang M., Cabanov A., Rojas K.T., Kaur K., Andrews S.F., Palm A.-K.E., Chen Y.-Q., Li Y., et al. Influenza Virus Vaccination Elicits Poorly Adapted B Cell Responses in Elderly Individuals. Cell Host Microbe. 2019;25:357–366. doi: 10.1016/j.chom.2019.01.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2019.01.002</ArticleId><ArticleId IdType="pmc">PMC6452894</ArticleId><ArticleId IdType="pubmed">30795982</ArticleId></ArticleIdList></Reference><Reference><Citation>Renia L., Goh Y.S., Rouers A., Le Bert N., Ni Chia W., Chavatte J.-M., Fong S., Chang Z.W., Zhuo N.Z., Tay M.Z., et al. Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose. Nat. Commun. 2022;13:4615. doi: 10.1038/s41467-022-32312-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-32312-1</ArticleId><ArticleId IdType="pmc">PMC9358634</ArticleId><ArticleId IdType="pubmed">35941158</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeffery-Smith A., Burton A.R., Lens S., Rees-Spear C., Davies J., Patel M., Gopal R., Muir L., Aiano F., Doores K.J., et al. SARS-CoV-2-specific memory B cells can persist in the elderly who have lost detectable neutralizing antibodies. J. Clin. Investig. 2022;132:e152042. doi: 10.1172/JCI152042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI152042</ArticleId><ArticleId IdType="pmc">PMC8759779</ArticleId><ArticleId IdType="pubmed">34843448</ArticleId></ArticleIdList></Reference><Reference><Citation>World Medical Association Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects. JAMA. 2013;310:2191–2194. doi: 10.1001/jama.2013.281053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2013.281053</ArticleId><ArticleId IdType="pubmed">24141714</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>